In:
Cancer, Wiley
Abstract:
Larotrectinib, a first‐in‐class tropomyosin receptor kinase (TRK) inhibitor, demonstrated robust and durable responses, extended survival benefit, and a favorable safety profile in adult patients with TRK fusion sarcomas. Testing for NTRK gene fusions should be incorporated into the clinical management of adult patients with various types of sarcomas to identify those suitable for targeted therapy.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1